Sprycel

Risk of severe myelosuppression. Obtain CBCs every 2 weeks for 12 weeks, then every 3 months thereafter (chronic phase CML) or weekly for the first 2 months, then monthly thereafter (advanced phase CML or Ph+ ALL). In children with Ph+ ALL on combination chemotherapy, obtain CBCs before starting each block of chemotherapy and as clinically indicated; do every 2 days until recovery during consolidation. Monitor for cardiac dysfunction; treat appropriately if occur. Congenital long QT syndrome. Proarrhythmic conditions. Cumulative high-dose anthracycline therapy. Hypokalemia, hypomagnesemia; correct electrolyte imbalances before starting and during therapy. Monitor for pleural effusions. Increased risk of pulmonary arterial hypertension (PAH); evaluate for signs/symptoms of underlying cardiopulmonary disease before and during treatment; permanently discontinue if occurs. Permanently discontinue if severe skin reactions (eg, Stevens-Johnson syndrome) occur. Increased risk of tumor lysis syndrome in advanced stage disease and/or high tumor burden. Maintain adequate hydration. Correct uric acid levels before therapy and monitor electrolytes. Monitor AST/ALT at baseline, monthly, or as needed during therapy. Hepatic impairment. Elderly. Embryo-fetal toxicity. Pregnancy: avoid. Advise females of reproductive potential and males (w. female partners) to use effective contraception during and for 30 days after the last dose. Nursing mothers: not recommended (during and for 2 weeks after the last dose).